Pharmaceutical care in transplantation: current challenges and future opportunities

In this commentary, authors review the importance of highly effective immunosuppression to the filed of solid organ transplantation and highlight the future scientific advancement required to further improve transplant patients' quality of life.

Go to the profile of Nanomedicine
Nov 20, 2019
0
0

The United Network for Organ Sharing, the nonprofit organization that contracts with the government to manage the country's organ transplantation system, reports that over 750,000 transplants have been performed in the USA since 1988. Over 113,000 individuals are currently listed as candidates on waiting lists for organs. In 2016, just over 23,000 referrals to organ procurement organizations met criteria for eligible or imminent death per the Organ Procurement and Transplantation Network definition, leading to almost 10,000 deceased donors for transplant.

Although a variety of clinical factors among the donors and recipients affect the success of individual solid organ transplants, outcomes and developments across the field continue to broadly improve over time. Most recently, the field has seen expansion and preliminary successes in vascularized composite allotransplantation, or the transplantation of multiple tissues as a functional unit.

In this commentary, published in the journal Nanodmedicine, Jordan Covvey (Duquesne University School of Pharmacy; PA, USA) and Erin E Mancl (Mallinckrodt Pharmaceuticals; NJ, USA) detail the importance of highly effective immunosuppression to the filed of solid organ transplantation and highlight the future scientific advancement required to further improve transplant patients' quality of life.

Read the full commentary, for free, in Nanomedicine now >>

Go to the profile of Nanomedicine

Nanomedicine

Journal, Future Science Group

Nanomedicine (Impact Factor: 4.717 [2018), is an award-winning peer-reviewed journal from Future Science Group, available in both print and online formats. Published 24 times per year, Nanomedicine is a uniquely medicine-focused journal, addressing the important challenges and advances in medical nanoscale-structured material and devices, biotechnology devices and molecular machine systems and nanorobotics, delivering this essential information in concise, clear and attractive article formats. Nanomedicine is listed by Medline/PubMed, Science Citation Index Expanded, Journal Citation Reports/Science Edition, Current Contents/Life Sciences and the Biotechnology Citation Index. Professor Kostas Kostarelos (Nanomedicine Lab, University of Manchester, UK) is the journal’s Senior Editor. You can find out more about Nanomedicine on our website (http://www.futuremedicine.com/loi/nnm), including the journal’s aims and scope and details of our international editorial board.

No comments yet.